Acinar with ductal and mucinous adenocarcinoma of prostate cancer complicated with lung metastasis: a case report and literature review

Ann Palliat Med. 2021 Feb;10(2):2366-2370. doi: 10.21037/apm-20-386. Epub 2020 Jun 23.

Abstract

Acinar adenocarcinoma, ductal adenocarcinoma and mucinous adenocarcinoma are the subtypes of prostate cancer (PCa). Most of the pathological types of PCa are acinar adenocarcinoma, while ductal adenocarcinoma and mucinous adenocarcinoma are uncommon. The case of acinar adenocarcinoma with ductal and mucinous adenocarcinoma has not been reported before. Herein, we report a treatment experience involving a 72-year-old man who presented similarly as most PCa patients, but the pathologic diagnosis was acinar adenocarcinoma with focal ductal and mucinous adenocarcinoma differentiating. Besides, this case is associated with lung metastasis, after radical prostatectomy (RP) and endocrine therapy the pulmonary nodule exerted a shrinking trend and the PSA level of this patient is still maintained at 0 ng/ mL till now. Through literature review, we found that patients who diagnosed as mixed pathological type of PCa had a lower survivor than pure PCa patients. Furthermore, there is no corresponding consensus or guideline for treating such multiple differentiated PCa patients. Surprisingly, this patient showed a high sensitivity to androgen deprivation therapy (ADT). Although the tumor presented aggressiveness, the followup results were satisfactory and we will continue to pay attention to his physical condition. We report this case to provide a treatment strategy for the patients with multi-differentiated PCa complicated with organ metastases.

Keywords: Prostate cancer (PCa); androgen deprivation therapy (ADT); case report; ductal adenocarcinoma; mucinous adenocarcinoma.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adenocarcinoma, Mucinous*
  • Aged
  • Androgen Antagonists / therapeutic use
  • Humans
  • Lung Neoplasms*
  • Male
  • Prostate-Specific Antigen
  • Prostatic Neoplasms*

Substances

  • Androgen Antagonists
  • Prostate-Specific Antigen